Search Results

You are looking at 1 - 10 of 137 items for :

  • "myelodysplastic syndromes" x
Clear All
Full access

Peter L. Greenberg, Eyal Attar, John M. Bennett, Clara D. Bloomfield, Carlos M. De Castro, H. Joachim Deeg, James M. Foran, Karin Gaensler, Guillermo Garcia-Manero, Steven D. Gore, David Head, Rami Komrokji, Lori J. Maness, Michael Millenson, Stephen D. Nimer, Margaret R. O'Donnell, Mark A. Schroeder, Paul J. Shami, Richard M. Stone, James E. Thompson and Peter Westervelt

Overview T he myelodysplastic syndromes (MDS) represent myeloid clonal hemopathies with relatively heterogeneous spectrums of presentation. The major clinical problems in these disorders are morbidities caused by cytopenias and the potential

Full access

Peter L. Greenberg, Eyal Attar, John M. Bennett, Clara D. Bloomfield, Uma Borate, Carlos M. De Castro, H. Joachim Deeg, Olga Frankfurt, Karin Gaensler, Guillermo Garcia-Manero, Steven D. Gore, David Head, Rami Komrokji, Lori J. Maness, Michael Millenson, Margaret R. O’Donnell, Paul J. Shami, Brady L. Stein, Richard M. Stone, James E. Thompson, Peter Westervelt, Benton Wheeler, Dorothy A. Shead and Maoko Naganuma

myelodysplastic syndromes (MDS) represent myeloid clonal hemopathies with relatively heterogeneous spectrums of presentation. The major clinical problems in these disorders are morbidities caused by patients’ cytopenias and the potential for MDS to evolve into

Full access

Peter L. Greenberg, Richard M. Stone, Rafael Bejar, John M. Bennett, Clara D. Bloomfield, Uma Borate, Carlos M. De Castro, H. Joachim Deeg, Amy E. DeZern, Amir T. Fathi, Olga Frankfurt, Karin Gaensler, Guillermo Garcia-Manero, Elizabeth A. Griffiths, David Head, Virginia Klimek, Rami Komrokji, Lisa A. Kujawski, Lori J. Maness, Margaret R. O’Donnell, Daniel A. Pollyea, Bart Scott, Paul J. Shami, Brady L. Stein, Peter Westervelt, Benton Wheeler, Dorothy A. Shead and Courtney Smith

, participants will be able to: Integrate into professional practice the updates to the NCCN Guidelines for Myelodysplastic Syndromes Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Myelodysplastic

Full access

Peter L. Greenberg

Revised International Prognostic Scoring System (IPSS-R) for clinically evaluating patients with MDS The myelodysplastic syndromes (MDS) consist of a heterogeneous spectrum of myeloid clonal hemopathies. Factors associated with the clinical and

Full access

Mikkael A. Sekeres

T he first description of patients with a blood picture compatible with the myelodysplastic syndromes (MDS) was published at the beginning of the 20th century, 1 and the first MDS case series was published in the early 1970s. 2 This places the

Full access

Rafael Bejar

Optimizing Therapy for Individual Patients Myelodysplastic syndromes (MDS) are a group of bone marrow failure disorders characterized by ineffective hematopoiesis. For many patients with lower-risk MDS, life expectancy can exceed 5 years. However

Full access

Arjan A. van de Loosdrecht and Theresia M. Westers

Morphology is not always clear-cut in the diagnosis of myelodysplastic syndromes (MDS). 1 Hence, in clinical practice, cytogenetics is currently considered the most important parameter because the karyotype has diagnostic, prognostic, and

Full access

Peter L. Greenberg, Leon E. Cosler, Salvatore A. Ferro and Gary H. Lyman

their competitors. Dr. Lyman is on the speakers' bureau for Amgen Inc. References 1. Greenberg PL . Clinical and prognostic characterization of myelodysplastic syndromes . In: Greenberg PL, ed. Myelodysplastic Syndromes: Clinical and

Full access

Rafael Bejar and Peter L. Greenberg

Molecular profiling has identified critical genetic derangements contributing to the clinical phenotypes of patients with myelodysplastic syndromes (MDS) and related disorders. Molecular insights have demonstrated how specific somatic gene

Full access

Peter L. Greenberg, Richard M. Stone, Aref Al-Kali, Stefan K. Barta, Rafael Bejar, John M. Bennett, Hetty Carraway, Carlos M. De Castro, H. Joachim Deeg, Amy E. DeZern, Amir T. Fathi, Olga Frankfurt, Karin Gaensler, Guillermo Garcia-Manero, Elizabeth A. Griffiths, David Head, Ruth Horsfall, Robert A. Johnson, Mark Juckett, Virginia M. Klimek, Rami Komrokji, Lisa A. Kujawski, Lori J. Maness, Margaret R. O'Donnell, Daniel A. Pollyea, Paul J. Shami, Brady L. Stein, Alison R. Walker, Peter Westervelt, Amer Zeidan, Dorothy A. Shead and Courtney Smith

myelodysplastic syndromes (MDS) represent myeloid clonal hemopathies with a relatively heterogeneous spectrum of presentation. Major clinical problems associated with these disorders are morbidities caused by cytopenias and the potential for MDS to evolve into